--- title: "Sana Biotechnology (SANA) news: class action and offering" url: "https://aibio.space/companies/sana-biotechnology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SANA class action and offering news: Sana Biotechnology securities class action is stayed after second amended complaint. Sana Biotechnology, Inc." --- SANA Sana Biotechnology, Inc. NASDAQ · United States # Sana Biotechnology (SANA) news SANA class action and offering news Legal · 2026-08-10 ## [Sana Biotechnology securities class action is stayed after second amended complaint](https://aibio.space/news/sana-biotechnology-securities-class-action-stayed-after-second-amended/) The Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed. ## Latest Sana Biotechnology news 1. 2025-08-06 Financings [Sana Biotechnology prices $75.0 million offering at $3.35 a share](https://aibio.space/news/sana-biotechnology-prices-75-0-million-offering-3-35-share/) Sana sold 20,895,522 shares at $3.35 plus pre-funded warrants for 1,492,537 more, with about $70.0 million in estimated net proceeds. It reported about $90.1 million in cash at July 31, 2025 and estimates $40.0 million to $45.0 million in facility impairments. ## Sana Biotechnology at a glance - **Ticker**: SANA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $160.5 million ### Related companies - [Arvinas](https://aibio.space/companies/arvinas/) NASDAQ: ARVN - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) NASDAQ: SLDB - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) NASDAQ: FLNA - [Absci](https://aibio.space/companies/absci/) NASDAQ: ABSI - [TScan Therapeutics](https://aibio.space/companies/tscan-therapeutics/) NASDAQ: TCRX - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX - [Boundless Bio](https://aibio.space/companies/boundless-bio/) NASDAQ: BOLD - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) NASDAQ: PVLA ### Also on NASDAQ - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) TGTX - [Lifecore Biomedical](https://aibio.space/companies/lifecore-biomedical/) LFCR - [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) SCTX - [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) XLO - [908 Devices](https://aibio.space/companies/908-devices/) MASS - [Senti Biosciences Holdings](https://aibio.space/companies/senti-biosciences/) SNTI ## Sana Biotechnology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$132.0 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | [$215.7 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | | Net income (loss) | [-$244.2 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | [-$266.8 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | | Cash from operations | [-$143.8 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | [-$223.2 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | | Cash and equivalents | [$71.9 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526342395/) | [$127.6 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | | Short-term investments | [$66.5 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526342395/) | [$24.9 million](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $57.1 million, plus short-term investments of $103.4 million, $160.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Sana Biotechnology Is there a class action against Sana Biotechnology? Our latest story on this, dated Aug 10, 2026: "Sana Biotechnology securities class action is stayed after second amended complaint". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sana-biotechnology-securities-class-action-stayed-after-second-amended/). Has Sana Biotechnology raised money recently? Our latest story on this, dated Aug 6, 2025: "Sana Biotechnology prices $75.0 million offering at $3.35 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sana-biotechnology-prices-75-0-million-offering-3-35-share/). What is the ticker symbol of Sana Biotechnology? Sana Biotechnology, Inc. trades under the ticker SANA on NASDAQ. Where is Sana Biotechnology listed? Sana Biotechnology, Inc. is listed on NASDAQ. What is the SEC CIK of Sana Biotechnology? The SEC Central Index Key (CIK) for Sana Biotechnology, Inc. is 1770121. Its filings are on SEC EDGAR. How many shares does Sana Biotechnology have outstanding? 299,360,637 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Sana Biotechnology listed under? Our directory records Sana Biotechnology, Inc. under United States. What does Sana Biotechnology do? Our directory classifies Sana Biotechnology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Sana Biotechnology? The ISIN recorded for Sana Biotechnology, Inc. is US7995661045. Does aibio.space cover Sana Biotechnology? aibio.space lists Sana Biotechnology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Sana Biotechnology incorporated? SEC records list its state or country of incorporation as DE. Is Sana Biotechnology profitable? Sana Biotechnology, Inc. reported a net loss of $244.2 million for the fiscal year ended Dec 31, 2025, and used $143.8 million of cash in operations, per its annual report to the SEC. How much does Sana Biotechnology spend on research and development? $132.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Sana Biotechnology have? $160.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Sana Biotechnology (SANA) stock news? Our latest story on Sana Biotechnology, dated Aug 10, 2026: "Sana Biotechnology securities class action is stayed after second amended complaint". The Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed. [Source](https://aibio.space/news/sana-biotechnology-securities-class-action-stayed-after-second-amended/). ## Investor discussion: Sana Biotechnology Members talk about Sana Biotechnology (SANA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Sana Biotechnology, newest first. Each line links the filing it comes from. 1. 2026-05-15 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1770121/000119312526226674/d135844d8k.htm) 2. 2026-04-13 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1770121/000119312526152868/sana-20260410.htm) 3. 2026-03-03 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088784/d113291ds3asr.htm) 4. 2025-08-11 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1770121/000177012125000010/sana-20250630.htm) 5. 2025-08-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1770121/000119312525174567/d29317d424b5.htm) 6. 2025-05-08 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1770121/000095017025066943/sana-20250331.htm) 7. 2025-05-08 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1770121/000119312525116035/d884842d424b5.htm) 8. 2025-03-17 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1770121/000095017025040254/sana-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SANA on TradingView](https://www.tradingview.com/symbols/NASDAQ-SANA/). ## SEC filings and registration - **SEC name**: Sana Biotechnology, Inc. - **CIK**: 1770121 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: SANA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA - **Phone**: (206) 701-7914 - **Shares outstanding**: 299,360,637 as of 2026-08-03 (10-Q filed 2026-08-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1770121/000119312526384405/d170343d8k.htm) filed 2026-09-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1770121/000119312526342395/sana-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1770121/000119312526342371/sana-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1770121/000119312526259532/sana-20260604.htm) filed 2026-06-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1770121/000119312526226674/d135844d8k.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1770121/000119312526216769/sana-20260331.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/sana-20260511.htm) filed 2026-05-11 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1770121/000119312526174883/d42230ddef14a.htm) filed 2026-04-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001770121), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Sana Biotechnology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SANA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Sana Biotechnology, Inc. - **Ticker**: SANA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US7995661045 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SANA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sana-biotechnology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sana Biotechnology (SANA) news: class action and offering", 2026-10-31, https://aibio.space/companies/sana-biotechnology/